Cargando…

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs

The P2X7 ion channel is a key sensor for extracellular ATP and a key trigger of sterile inflammation. Intravenous injection of nanobodies that block P2X7 has shown to be beneficial in mouse models of systemic inflammation. P2X7 has also emerged as an attractive therapeutic target for inflammatory br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinto-Espinoza, Carolina, Guillou, Charlotte, Rissiek, Björn, Wilmes, Maximilian, Javidi, Ehsan, Schwarz, Nicole, Junge, Marten, Haag, Friedrich, Liaukouskaya, Nastassia, Wanner, Nicola, Nicke, Annette, Stortelers, Catelijne, Tan, Yossan-Var, Adriouch, Sahil, Magnus, Tim, Koch-Nolte, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589454/ https://www.ncbi.nlm.nih.gov/pubmed/36299894 http://dx.doi.org/10.3389/fphar.2022.1029236

Ejemplares similares

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
por: Eichhoff, Anna Marei, et al.
Publicado: (2019)

Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions
por: Wilmes, Maximilian, et al.
Publicado: (2022)

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
por: Demeules, Mélanie, et al.
Publicado: (2020)

A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo
por: Gondé, Henri, et al.
Publicado: (2021)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo
por: Demeules, Mélanie, et al.
Publicado: (2022)

ASC nanobodies to counteract the consequences of inflammasome activation
por: Adriouch, Sahil, et al.
Publicado: (2022)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
por: Menzel, Stephan, et al.
Publicado: (2018)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy
por: Jank, Larissa, et al.
Publicado: (2019)

P2X7 on Mouse T Cells: One Channel, Many Functions
por: Rissiek, Björn, et al.
Publicado: (2015)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
por: Bannas, Peter, et al.
Publicado: (2015)

Delivery of an anti‐transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons
por: Gomes, João R., et al.
Publicado: (2018)

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation
por: Eden, Thomas, et al.
Publicado: (2018)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Generation and Characterization of Specific Monoclonal Antibodies and Nanobodies Directed Against the ATP-Gated Channel P2X4
por: Bergmann, Philine, et al.
Publicado: (2019)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody
por: Kaczmarek-Hajek, Karina, et al.
Publicado: (2018)

Recombinant expression of nanobodies and nanobody-derived immunoreagents
por: de Marco, Ario
Publicado: (2020)

Alternative Splicing of the N-Terminal Cytosolic and Transmembrane Domains of P2X7 Controls Gating of the Ion Channel by ADP-Ribosylation
por: Schwarz, Nicole, et al.
Publicado: (2012)

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020)

Extracellular NAD(+) shapes the Foxp3(+) regulatory T cell compartment through the ART2–P2X7 pathway
por: Hubert, Sandra, et al.
Publicado: (2010)

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT
por: Unger, Mandy, et al.
Publicado: (2015)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Large Diversity of Functional Nanobodies from a Camelid Immune Library Revealed by an Alternative Analysis of Next-Generation Sequencing Data
por: Deschaght, Pieter, et al.
Publicado: (2017)

Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia
por: Rissiek, Björn, et al.
Publicado: (2017)

Nanobodies that Neutralize HIV
por: Weiss, Robin A., et al.
Publicado: (2019)

The Therapeutic Potential of Nanobodies
por: Jovčevska, Ivana, et al.
Publicado: (2019)

Special Issue: Nanobody
por: Chames, Patrick, et al.
Publicado: (2020)

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex
por: Desmyter, Aline, et al.
Publicado: (2017)

Selecting Nanobodies Specific for the Epidermal Growth Factor from a Synthetic Nanobody Library
por: Serrano-Rivero, Yunier, et al.
Publicado: (2023)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
por: Hambach, Julia, et al.
Publicado: (2020)

T Cells of Different Developmental Stages Differ in Sensitivity to Apoptosis Induced by Extracellular NAD
por: Haag, Friedrich, et al.
Publicado: (2002)

Nanobody-Displaying Flagellar Nanotubes
por: Klein, Ágnes, et al.
Publicado: (2018)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

Immunogenicity Risk Profile of Nanobodies
por: Ackaert, Chloé, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cd0nao2jn5h94dcj0m1eruhahb